The Impact of Psilocybin on Pain in Fibromyalgia Patients and Healthy Volunteers: a Multicenter Trial

This therapeutic exploratory Phase II trial (n=44) aims to assess the effects of low doses of psilocybin (5-10mg) on pain endurance and ratings of painfulness in fibromyalgia patients and healthy volunteers.

Conducted across multiple centres, including Maastricht University, the study is investigating the impact of psilocybin on pain tolerance, pressure pain threshold, and subjective pain ratings. Additionally, the trial will evaluate secondary outcomes such as mood, cognition, personality, and psychedelic experience.

Fibromyalgia patients and healthy volunteers meeting specific criteria will participate, with assessments conducted at various time points during each experimental session. The trial, sponsored by Maastricht University and supported by the Usona Institute, is authorised by the Competent Authority and has a favourable opinion from the Ethics Committee.

Topic Fibromyalgia Healthy Subjects
Compound Psilocybin
Country Netherlands
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.

Usona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.